The company also added Giuseppe Dastoli as vice president of business and commercial operations in Europe and Silvia Comis will be responsible for clinical development in Europe...Chiron Corp., of Emeryville, Calif., said Howard Pien, president and CEO, was elected to the board of California Healthcare Institute

AVI BioPharma Inc., of Portland, Ore., added James Gourzis as a consultant to provide strategic direction and management of the company's regulatory and clinical development programs...and Patti Ketchner to vice president and corporate controller

ArQule Inc., Woburn, Mass., appointed Adam Craig vice president, clinical development and medical director, and Louise Mawhinney vice president, finance and chief financial officer

Cytogen Corp., of Princeton, N.J., added Christopher Schnittker as vice president and chief financial officer...Encysive Pharmaceuticals Inc., of Houston, appointed Terrance Coyne chief medical officer, vice president of clinical development and an officer...Incyte Corp., of Palo Alto, Calif., appointed John Keller executive vice president and chief business officer

Perlegen Sciences Inc., of Mountain View, Calif., added Mark McCamish as chief medical officer and vice president of clinical development...West Pharmaceutical Services Inc., of Lionville, Pa., appointed William Federici vice president and chief financial officer

Also, Jan van Heek will oversee Genzyme Biosurgery and Genzyme Genetics...Ann Merrifield was appointed president of Genzyme Biosurgery, and Duke Collier will direct Genzyme's molecular oncology and cardiovascular business units

Indevus Pharmaceuticals Inc., of Lexington, Mass., elected Cheryl Morley and Stephen McCluski to its board...Newron Pharmaceuticals SpA, of Milan, Italy, appointed Stefano Rossetti vice president, clinical development

City of Hope in Los Angeles named Michael Friedman president and CEO...It also appointed Dorothy Bray to serve as clinical development adviser

Alkermes Inc., of Cambridge, Mass., elected Gerri Henwood and Paul Mitchell to its board...Ecopia BioSciences Inc., of Montreal, appointed Gervais Dionne and Louis de Repentigny to its scientific advisory board...Paladin Labs Inc., of Montreal, appointed Aldo Baumgartner and Michael Cloutier to its board

Abgenix Inc., of Fremont, Calif., appointed Kenneth Lee and Thomas Wiggans to its board...Ecopia BioSciences Inc., of Montreal, appointed Gervais Dionne and Louis de Repentigny to its scientific advisory board...Pyrosequencing AB, of Uppsala, Sweden, elected Jeff Bork to its board and intends to name him chairman

Alkermes Inc., of Cambridge, Mass., appointed Kathryn Biberstein vice president and general counsel and Trevor Mundel vice president, clinical development...Elliot Ehrich was named vice president, science and development and chief medical officer, while Susanne McGown has the added responsibility for all business development efforts

Hemispherx Biopharma Inc., of Philadelphia, appointed James Knill vice president of clinical development for its HIV/AIDS division and David Fedorczyk director of clinical and statistical affairs...and named Sheila Benson a consultant in its scientific and technical group

Maxygen Inc., of Redwood City, Calif., said its subsidiary, Maxygen ApS, appointed Elliot Goldstein senior vice president, clinical development and Denmark operations...RedStorm Scientific, of Houston, appointed John Carpenter and Joshua Wand to its scientific advisory board...Thios Pharmaceuticals Inc., of Emeryville, Calif., appointed Bruce Hironaka CEO and named him to its board

and Joanne Harack vice president, human resources and corporate communications...Chiral Quest Inc., of State College, Pa., added Barry Sharpless and James Collman to its scientific advisory board

Other members include Roger Guillemin, Clive Meanwell, John Glaspy, Douglas Green and Eugene Schiff...Proneuron Biotechnologies Inc., of Los Angeles, appointed David Snyder vice president, clinical development

Renovis Inc., of South San Francisco, added John Doyle as vice president of finance and chief financial officer, Jacob Huff as vice president of clinical development, Michael Kelly as senior director of chemistry, John Kollins as vice president of business development and Paula Serbin as vice president of human resources

Inc., of Bothell, Wash., appointed Gordon Brandt executive vice president of science and clinical development

Avigen Inc., of Alameda, Calif., added Glenn Pierce as vice president, clinical development...Tensor Biosciences, of Irvine, Calif., appointed Joseph Coyle, Richard Morris, Roger Nicoll and Samuel Deadwyler to its scientific advisory board

AtheroGenics Inc., of Atlanta, elected David Bearman to its board and to serve on its audit committee...Avigen Inc., of Alameda, Calif., added Glenn Pierce as vice president, clinical development